Daikos George L, da Cunha Clóvis Arns, Rossolini Gian Maria, Stone Gregory G, Baillon-Plot Nathalie, Tawadrous Margaret, Irani Paurus
Department of Medicine, National and Kapodistrian University of Athens, 115-27 Athens, Greece.
Hospital Nossa Senhora das Graças, Curitiba 80810-040, PR, Brazil.
Antibiotics (Basel). 2021 Sep 18;10(9):1126. doi: 10.3390/antibiotics10091126.
is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes. Ceftazidime-avibactam is a combination antimicrobial agent comprising ceftazidime, a third-generation semisynthetic cephalosporin, and avibactam, a novel non-β-lactam β-lactamase inhibitor. This review explores the potential role of ceftazidime-avibactam for the treatment of infections. Ceftazidime-avibactam has good in vitro activity against relative to comparator β-lactam agents and fluoroquinolones, comparable to amikacin and ceftolozane-tazobactam. In Phase 3 clinical trials, ceftazidime-avibactam has generally demonstrated similar clinical and microbiological outcomes to comparators in patients with complicated intra-abdominal infections, complicated urinary tract infections or hospital-acquired/ventilator-associated pneumonia caused by . Although real-world data are limited, favourable outcomes with ceftazidime-avibactam treatment have been reported in some patients with MDR and XDR infections. Thus, ceftazidime-avibactam may have a potentially important role in the management of serious and complicated infections, including those caused by MDR and XDR strains.
是一种机会性革兰氏阴性病原体，可引起一系列严重感染，这些感染往往难以治疗，因为这种病原体可表达多种耐药机制，包括多重耐药（MDR）和广泛耐药（XDR）表型。头孢他啶-阿维巴坦是一种复方抗菌药物，由第三代半合成头孢菌素头孢他啶和新型非β-内酰胺类β-内酰胺酶抑制剂阿维巴坦组成。本综述探讨了头孢他啶-阿维巴坦在治疗感染中的潜在作用。相对于对照β-内酰胺类药物和氟喹诺酮类药物，头孢他啶-阿维巴坦对具有良好的体外活性，与阿米卡星和头孢洛扎-他唑巴坦相当。在3期临床试验中，对于由引起的复杂性腹腔内感染、复杂性尿路感染或医院获得性/呼吸机相关性肺炎患者，头孢他啶-阿维巴坦总体上显示出与对照药物相似的临床和微生物学结果。尽管真实世界的数据有限，但在一些多重耐药和广泛耐药感染患者中已报道了头孢他啶-阿维巴坦治疗的良好结果。因此，头孢他啶-阿维巴坦在严重和复杂性感染的管理中可能具有潜在的重要作用，包括由多重耐药和广泛耐药菌株引起的感染。
